Compare Stocks: ORIC, ACAD, CELC, and PBLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$5.03B	0.81	1.69 million shs	1.78 million shs
CELC Celcuity	$92.79 -0.5%	$94.57	$44.16 ▼ $151.02	$4.52B	0.21	1.69 million shs	543,219 shs
ORIC Oric Pharmaceuticals	$13.50 +4.4%	$10.15	$7.23 ▼ $14.93	$1.40B	1.02	1.76 million shs	1.29 million shs
PBLS Parabilis Medicines	$34.98 -1.7%	$29.99	$24.51 ▼ $36.82	$4.13B	N/A	417,668 shs	279,770 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+10.60%	+30.40%	+22.73%
CELC Celcuity	0.00%	+7.42%	-18.25%	-29.20%	+109.98%
ORIC Oric Pharmaceuticals	0.00%	+21.95%	+23.40%	+52.54%	+36.64%
PBLS Parabilis Medicines	0.00%	+2.94%	+15.22%	+3,497,999,900.00%	+3,497,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$29.21 +2.7%	$24.39	$19.69 ▼ $29.48	$5.03B	0.81	1.69 million shs	1.78 million shs
CELC Celcuity	$92.79 -0.5%	$94.57	$44.16 ▼ $151.02	$4.52B	0.21	1.69 million shs	543,219 shs
ORIC Oric Pharmaceuticals	$13.50 +4.4%	$10.15	$7.23 ▼ $14.93	$1.40B	1.02	1.76 million shs	1.29 million shs
PBLS Parabilis Medicines	$34.98 -1.7%	$29.99	$24.51 ▼ $36.82	$4.13B	N/A	417,668 shs	279,770 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+12.91%	+10.60%	+30.40%	+22.73%
CELC Celcuity	0.00%	+7.42%	-18.25%	-29.20%	+109.98%
ORIC Oric Pharmaceuticals	0.00%	+21.95%	+23.40%	+52.54%	+36.64%
PBLS Parabilis Medicines	0.00%	+2.94%	+15.22%	+3,497,999,900.00%	+3,497,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$33.44	14.49% Upside
CELC Celcuity	2.82	Moderate Buy	$155.18	67.24% Upside
ORIC Oric Pharmaceuticals	2.75	Moderate Buy	$19.27	42.76% Upside
PBLS Parabilis Medicines	3.00	Buy	$41.67	19.12% Upside

Current Analyst Ratings Breakdown

Latest ORIC, ACAD, CELC, and PBLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $37.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$23.00 ➝ $25.00
8/5/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$35.00 ➝ $36.00
7/29/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/29/2026	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.50
7/21/2026	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$34.00 ➝ $36.00
7/21/2026	ACAD ACADIA Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$24.00 ➝ $25.00
7/17/2026	ORIC Oric Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	CELC Celcuity	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.70	$0.89 per share	32.93	$7.25 per share	4.03
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.90 per share	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.16	29.51	23.76	33.42%	9.03%	6.79%	N/A
CELC Celcuity	-$177.04M	-$3.90	N/A	4,639.50	N/A	N/A	-244.61%	-50.22%	8/13/2026 (Estimated)
ORIC Oric Pharmaceuticals	-$129.47M	-$1.35	N/A	N/A	N/A	N/A	-35.35%	-33.39%	8/11/2026 (Estimated)
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ORIC, ACAD, CELC, and PBLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	N/A	N/A	N/A	$4.42 million	N/A
8/11/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.36	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/3/2026	Q2 2026	ORIC Oric Pharmaceuticals	-$0.3594	-$0.38	-$0.0207	-$0.38	N/A	N/A
5/14/2026	Q1 2026	CELC Celcuity	-$1.07	-$0.97	+$0.10	-$0.97	$2.94 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
CELC Celcuity	6.04	12.31	12.31
ORIC Oric Pharmaceuticals	N/A	13.19	13.19
PBLS Parabilis Medicines	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CELC Celcuity	63.33%
ORIC Oric Pharmaceuticals	95.05%
PBLS Parabilis Medicines	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CELC Celcuity	13.33%
ORIC Oric Pharmaceuticals	5.70%
PBLS Parabilis Medicines	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
CELC Celcuity	40	48.77 million	42.27 million	Optionable
ORIC Oric Pharmaceuticals	80	103.65 million	97.75 million	Optionable
PBLS Parabilis Medicines	N/A	118.15 million	N/A	N/A

ORIC, ACAD, CELC, and PBLS Headlines

Recent News About These Companies

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts

August 1, 2026 | marketbeat.com

Parabilis Medicines, Inc. (NASDAQ:PBLS) Sees Significant Increase in Short Interest

July 14, 2026 | marketbeat.com

Parabilis Medicines, Inc.'s Quiet Period Set To Expire on July 20th (NASDAQ:PBLS)

July 13, 2026 | marketbeat.com

This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

July 6, 2026 | benzinga.com

PBLS Parabilis Medicines, Inc.

July 2, 2026 | seekingalpha.com

Guy Levy Acquires 500,000 Shares of Parabilis Medicines (NASDAQ:PBLS) Stock

June 30, 2026 | insidertrades.com

This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested

June 27, 2026 | fool.com

Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?

June 20, 2026 | fool.com

Insider Buying: Parabilis Medicines (NASDAQ:PBLS) Director Acquires 8,435 Shares of Stock

June 17, 2026 | insidertrades.com

Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline

June 15, 2026 | finance.yahoo.com

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

June 14, 2026 | genengnews.comG

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 13, 2026 | finance.yahoo.com

Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials

May 22, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC, ACAD, CELC, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.21 +0.76 (+2.67%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$28.86 -0.36 (-1.22%)

As of 08/7/2026 07:59 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Celcuity NASDAQ:CELC

$92.79 -0.46 (-0.49%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$92.75 -0.04 (-0.04%)

As of 08/7/2026 07:37 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Oric Pharmaceuticals NASDAQ:ORIC

$13.50 +0.57 (+4.41%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$12.38 -1.12 (-8.33%)

As of 08/7/2026 08:00 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Parabilis Medicines NASDAQ:PBLS

$34.98 -0.60 (-1.69%)

As of 08/7/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORIC, ACAD, CELC, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORIC, ACAD, CELC, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORIC, ACAD, CELC, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC, ACAD, CELC, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Celcuity NASDAQ:CELC

Oric Pharmaceuticals NASDAQ:ORIC

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORIC, ACAD, CELC, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORIC, ACAD, CELC, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORIC, ACAD, CELC, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC, ACAD, CELC, and PBLS Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Celcuity NASDAQ:CELC

Oric Pharmaceuticals NASDAQ:ORIC

Parabilis Medicines NASDAQ:PBLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools